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Original Article
A non-randomized study of safety and efficacy of heparin for DVT prophylaxis in
intracerebral haemorrhage
Mohammad Wasay1, Saqibuddin Khan2, Khawaja S Zaki3, Bhojo A. Khealani4, Ayeesha Kamal5, Iqbal Azam6,
Ismail A.Khatri7
Department of Neurology and Medicine1,3,4,5, Community Health Sciences+6, The Aga Khan University, Karachi, Pakistan, Department of Medicine2,
Abbasi Shaheed Hospital, Karachi, Department of Neurology7, Shifa International Hospitals, Islamabad.

Abstract
Objective: To evaluate the safety and efficacy of subcutaneous heparin for deep venous thrombosis (DVT)
prophylaxis in patients with intracerebral haemorrhage (ICH) during acute phase in comparison to elastic
stockings.
Methods: The diagnosis of ICH was based on imaging (CT or MRI) and DVT was based on Doppler ultrasound.
Results: A total of 458 patients were identified over a period of 5 years (1997-2001). Median age was 59 years
(range:12-99 years). Two hundred (44%) patients received heparin (heparin group) in addition to elastic
stockings and 258 (56%) patients were only given elastic stockings (stockings group). These two groups were
not randomized. Heparin was administered subcutaneously (SQ) in doses of 2500-5000 international units twice
daily. Two groups were matched for age (p=0.5), sex (p=0.28), presence of diabetes mellitus (p=0.14), cigarette
smoking (p=0.045) and presence of hydrocephalus or midline shift on CT/MRI (p= 0.87). One patient developed
DVT in control group while none developed DVT in heparin group (p=0.18). One patient had worsening of ICH
on repeat CT scan in Heparin group. This worsening was non fatal. Systemic haemorrhagic complications (non
fatal) were seen in 7 (14%) patients receiving heparin. Twenty five patients (12%) in heparin group and 52 (20%)
in control group died (p=0.02).
Conclusion: Subcutaneous heparin in doses of 2500-5000 units twice daily during acute phase in patients with
ICH may be safe for DVT prophylaxis. It was not superior to elastic stockings in a non-randomized comparison
to prevent DVT (JPMA 58:362;2008).

Introduction
The frequency of clinical deep venous thrombosis
(DVT) in patients with ischaemic stroke is 2-3%.1-3 The
absolute risk of fatal pulmonary embolism (PE) after
ischaemic stroke within first month is 1-2%.4-5 Exact
incidence of clinical DVT and PE in patients with
intracerebral haemorrhage (ICH) is not well known. It is
suggested that it is probably in the range of 3-5%.6
Risk of rebleeding is the major limiting factor when
considering these patients for DVT and PE prophylaxis with
heparin or low molecular weight heparin. Studies have
shown that risk of rebleed within first three months after
ICH in patients receiving no aspirin or heparin is about
0.5%.7 The only factor that predicted a higher recurrence
rate was lobar location of haemorrhage.8-9
The data regarding risk of rebleeding in patients
receiving heparin is scanty. One prospective study showed
that one out of 45 patients receiving unfractionated heparin
(UFH) 5000 units TID developed rebleed.10 Another
retrospective study showed that a subgroup of 22 patients
with ICH receiving long term anticoagulation had a 2.7
times increased risk of rebleeding as compared to non-
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anticoagulated patients.11 No cases of rebleeding were
identified in another study of 68 patients with ICH that were
treated with heparin.12
Our study represents a large cohort of patients with
primary intracerebral haemorrhage. The patients were either
treated with subcutaneous (SQ) heparin in addition to
elastic stockings or elastic stockings alone. Pneumatic
compression devices were not used in any patients. Patients
were not randomized and decision to start SQ heparin was
entirely based on physician preference. Despite being
retrospective and non-randomized, the study provides
useful information regarding natural history of rebleeding in
untreated patients, incidence of DVT and risk of rebleeding
in heparin treated patients.

Methods
Medical records of patients with diagnosis of
primary intracerebral haemorrhage were retrospectively
reviewed at the Aga Khan University Hospital, Karachi. The
diagnosis of ICH was based on Brain computerized
tomography (CT) or magnetic resonance imaging (MRI).
Patients with ICH due to thrombolysis or anticoagulation or
post traumatic ICH were excluded. Patients were divided
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into two groups based on use of heparin. Thigh high elastic
stockings were used in all patients while pneumatic or
sequential compression devices were not used in any
patient. The decision to start heparin and dosage of heparin
was entirely based on physician preference (nonrandomized). Heparin was administered subcutaneously in
doses of 2500 international units (71 patients) and 5000
international units (129 patients) twice daily. Patients were
daily examined for signs of clinical DVT (unilateral leg
swelling, warmth and redness).Cases of clinical DVT were
confirmed by Doppler ultrasound. Repeated scans were
performed in patients with clinical neurological worsening
to rule out expansion of haemorrhage.
Chi square test was used to compare both the groups
for baseline characteristics and outcome.

Results
Four hundred and fifty eight consecutive patients
were identified over a period of 5 years. Median age was 59
years (range: 12-99years). Two hundred (44%) patients
received heparin (heparin group) and 258 (56%) patients
did not receive heparin (stockings group). Heparin was
started on day 1 in 44 patients; day 2 in 93 patients; day 3 in
25 patients; and day 4-7 in 38 patients. The duration of
heparin treatment was less than 7 days in 12 patients; 7-14
days in 165 patients and more than 14 days in 23 patients.
Two groups were similar at baseline for age (p=0.5),
sex (p=0.28), presence of diabetes mellitus (p=0.14) and
presence of hydrocephalus or midline shift on CT/MRI (p=
0.87) and mean Glasgow Coma Score scale13 (p= 0.19).
One hundred and sixty nine (84%) patients in heparin group
were hypertensive as compared to 184 (72%) in stockings
group (p=0.01). One hundred and seventy (85%) in heparin
group had basal ganglia haemorrhage as compared to 164
(75%) in stockings group. One hundred and eighty patients
(90%) in heparin group and 201patients (78%) in stockings
group had Rankin score >3 on admission (p<0.001).
DVT was suspected clinically in seven patients
(stockings group=5, heparin group=2). Doppler evaluation
showed that only one patient developed DVT in stockings
group while none developed DVT in heparin group
(p=0.18). Repeat CT scans were performed in 45 patients
due to neurological worsening to rule out expansion of
haemorrhage (33 in heparin group and 12 in no-heparin
group). Follow up scans were done on day 2 (7 patients),
day 3(16 patients), day 4( 8 patients), day 5 (6 patients) and
after day 6( 8 patients). One patient had worsening of ICH
(20% increase in haematoma volume) on repeat CT scan in
heparin group. The location of this patient's haemorrhage
was parietal lobe and she was receiving 5000 units SQ
Heparin twice a day. This worsening was non fatal. No
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Table. Comparison of Heparin and stockings groups (baseline
characteristics and outcome).
variables
Mean age (years) + SD
Sex
Male
Female
Diabetes
Cigarette Smoking
Hypertension
Modified Rankin score >3
Basal ganglia haemorrhage
Mean GCS (Glasgow
coma scale)
Hydrocephalus or
midline shift on imaging
DVT
Worsening of ICH
Died

Heparin group stockings group
p- value
(n=200)
(n=258)
59 +33

57+29

0.5
0.28

108 (54%)
92 (46%)
57 (28%)
26 (13%)
169 (85%)
180 (90%)
170 (85%)

150 (58%)
108 (42%)
58 (22%)
19 (8%)
186 (72%)
201 (78%)
164 (75%)

0.14
0.045
0.01
0.01
0.05

7

6

0.19

56 (28%)
0
1
25 (12%)

74 (29%)
1
0
52 (20%)

0.87

0.02

patient in stockings group had worsening of ICH on repeat
CT scan. Heparin was discontinued in seven patients due to
systemic
haemorrhagic
complications
including
haematuria, superficial haematoma and excessive gum
bleeding. Twenty five patients (12%) in heparin group and
52 patients (20%) in stockings group died (p=0.02).
According to death records none of these patients had PE or
suspected PE as cause of death.

Discussion
The efficacy of heparin for DVT prophylaxis is well
established.14 There are no well-designed, large, prospective
studies supporting use of heparin for DVT prophylaxis in
patients with ICH. Our study presents one of the largest
cohorts of these patients that were treated with heparin.
We identified three patterns of practice among our
physicians for DVT prophylaxis in ICH patients. These
patterns were not based on evidence but physician
preferences. Fifty six percent patients did not receive
heparin for DVT prophylaxis, 30% received SQ heparin
5000 units twice a day and 14% received SQ heparin 2500
units twice a day.
The incidence of clinical DVT confirmed by
Doppler was extremely low in all groups (0.22%). We were
unable to identify factors contributing to low frequency of
clinical DVT in our patients with ICH as compared to
western studies (2-3%).6 No patient in Heparin group
developed DVT as compared to only one patient in
stockings group.Based on this information we cannot
comment on efficacy of heparin for DVT prophylaxis as
compared to stockings use. It is likely that conventional
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measures for DVT prophylaxis including early
mobilization, limb passive physiotherapy and compression
stockings are as good as heparin as there was no statistical
difference in the incidence of DVT in our patients.
The frequency of haematoma expansion due to
rebleed was very low (0.23%) when compared to reported
frequency by western literature (0.5%).7 The reason for this
low numbers is probably related to timings of initiation of
Heparin treatment. Increase in haematoma volume usually
occurs within first 24 hours. More than 75% patients in our
study were started on heparin after 24 hours. Repeat Head
CT scan was done more frequently in patients receiving
heparin. This may be the result of more cautious approach
of physicians when they were using heparin. Haemorrhagic
complications were seen more frequently in patients
receiving heparin than no-heparin group. One patient with
parietal haemorrhage in Heparin group developed
worsening of ICH on CT scan. Studies have shown that the
only factor that predicted higher rate of rebleed was lobar
location of hemorrhage.8 We do not know that worsening of
haemorrhage or rebleed in this patient was due to Heparin
or lobar location. Further studies may be able to guide that
patients with lobar haemorrhage on Heparin are at increased
risk of rebleed as compared to basal ganglia haemorrhage
on Heparin.
The study is limited by its retrospective nature. The
higher mortality in stockings group was difficult to explain
as the baseline modified Rankin score, and prior history of
hypertension both were more common in the heparin group.
These two factors have a prognostic implication. Our study
did not look at the volume of haemorrhage or severity of
neurological status on standardized scale (NIH stroke
scale), which is one of the limitations of our study. Major
limitations of study include non availability of Follow up or
repeat CT scan in majority of patients and reliance on
clinical examination for identification of DVT cases.
Although we believe that SQ heparin is safe for DVT
prophylaxis in patients with acute ICH but it was not
superior to conventional measures when compared to
stockings group. Recent studies have suggested that
intermittent pneumatic compression devices may be useful
in prevention of asymptomatic DVT.15,16 There are no trials
comparing efficacy of heparin versus pneumatic
compression devices for DVT prophylaxis. We are of the
opinion that value of DVT prophylaxis is highly dependent
upon the in-bed early mobilization of patient and heparin
therapy which can be considered a "replacement therapy".
Systematic review of previously published studies
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do not support reliable conclusions related to safety or
efficacy of heparin in patients with intracerebral
haemorrhage. Our study adds to the current pool of
information. A large, prospective, randomized trial is
warranted to further address this question which is faced by
practicing physicians routinely.
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